Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double- blind, controlled trial

Annals of Internal Medicine

Volumn 126, Issue 5, 1997, Pages 355-363

  Spruance, Spotswood L ^d   Pavia, Andrew T ^d   Mellors, John W ^d   Murphy, Robert ^d   Gathe Jr , Joseph ^d   Stool, Edward ^d   Jemsek, Joseph G ^a   Dellamonica, Pierre ^b   Cross, Anne ^c   Dunkle, Lisa ^c  

^a Nalle Clinic   (United States)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c BRISTOL MYERS SQUIBB   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; FLUCONAZOLE; PENTAMIDINE; RIFABUTIN; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANEMIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHALATIONAL DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

EID: 8044260834     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-5-199703010-00003     Document Type: Article

References (25)

1. Richman DD. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. Am J Med. 1990;88:8S-10S.
2. Riddler SA, Andersen RE, Mellors JW. Antiretroviral activity of stavudine (2′,3′-didehydro-3′- deoxythymidine, d4T). Antiviral Res. 1995;27:189-203.
3. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis. 1995;171 (Suppl 2):S113-7.
4. Browne MJ, Mayer KH, Chafee SB, Dudley MN, Posner MR, Steinberg SM, et al. 2′,3′-didehydro-3′- deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993;167:21-9.
5. Murray HW, Squires KE, Weiss W, Sledz S, Sacks HS, Hassett J, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis. 1995;171(Suppl 2):S123-30.
6. Petersen EA, Ramírez-Ronda CH, Hardy WD, Schwartz R, Sacks HS, Follansbee S, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis. 1995;171(Suppl 2):S131-9.
7. Griffith BP, Brett-Smith H, Kim G, Mellors JW, Chacko TM, Garner RB, et al. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis. 1996;173:1252-5.
8. 3: results of a double-blind randomized placebo-controlled study [Abstract]. In: Programs and Abstracts - 3rd Conference of Retroviruses and Opportunistic Infections. Washington, DC: Infectious Diseases Society of America; 1996:196.
9. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1992;41:1-11.
10. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep. 1987; 36(Suppl 1):1S-15S.
11. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996;335:1081-90.
12. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biomet. 1983;70:659-63.
13. Fleiss JL. Statistical Methods for Rates and Proportions. New York: Wiley; 1973.
14. Armitage P. Statistical methods in medical research. Oxford: Blackwell Scientific; 1971.
15. Wei LJ, Lachin. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. Journal of the American Statistical Association. 1984;499:652-61.
16. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 1995.
17. Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York: Wiley; 1991.
18. Wei LJ, Lin DY, Weissfel L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association. 1989;84:1065-73.
19. Dolin R, Amato DA, Fischl MA, Pettinelii C, Beltangady M, Liou SH, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Arch Intern Med. 1995;155:961-74
20. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelii C, Liou SH, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992;327:581-7.
21. Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. Ann Intern Med. 1994;120:360-8.
22. Gulick RM, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir, zidovudine and lamivudine [Abstract]. 11th International Conference on AIDS. Vancouver; 1996.
23. + cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995;333:1662-9.
24. Dudley MN, Graham KK, Kaul S, Geletko S, Dunkle L, Browne M, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis. 1992;166:480-5.
25. Pollard R, Peterson D, Hardy D, Pedneault L, McLaren C, Skovronski J, et al. Antiviral effect and safety of stavudine (d4T) and didanosine (ddl) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blind trial [Abstract]. In: Program and Abstracts - 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC: Infectious Diseases Society of America; 1996:197.